Italy-based medical diagnostics provider Esaote has received the US Food and Drug Administration (FDA) approval for its MyLab A50 and MyLab A70 ultrasound systems.
The FDA approval underscores the safety and clinical performance of the ultrasound systems, in line with the US standards, and allows their distribution in the US.
According to Esaote, MyLab A50 and A70 models are designed to provide flexibility and performance and are customised for various clinical settings.
The compact, battery-operated ultrasound systems are portable, addressing the mobility demands of healthcare professionals.
They are versatile, adapting to a wide range of diagnostic applications, from standard procedures to sophisticated imaging techniques, said Esaote.
Esaote North America Ultrasound Sales director Thomas Will said: “The new A-series emphasises user experience with a diverse range of interface options, including both a conventional and touch control panel.
“The devices boast an intuitive, easy-to-clean design that allows clinicians to operate efficiently and confidently.”
The MyLab A50 and A70 systems are equipped with the latest ultrasound features, including liver elastography and cardiology tools like strain analysis.
Leveraging artificial intelligence (AI) and advanced imaging technology, they enable comprehensive and detailed assessments.
Furthermore, the systems enhance diagnostic accuracy, equipping healthcare providers with reliable insights for patient care.
Earlier this year, Esaote unveiled MyLabC-Series, the new portable ultrasound line, at the European Congress of Radiology (Ecr) in Vienna.
MyLab C30 targets radiologists and, particularly, interventional practice.
It comes with a unique, cleanable control panel, a gesture-driven touchscreen, and a complete portfolio of probes and AI-driven tools.
